Literature DB >> 8946837

Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells.

C D Gimmi1, B W Morrison, B A Mainprice, J G Gribben, V A Boussiotis, G J Freeman, S Y Park, M Watanabe, J Gong, D F Hayes, D W Kufe, L M Nadler.   

Abstract

Given the plethora of well-documented breast carcinoma-associated antigens in humans including MAGE-1, -2 and -3, mutated p53, p21ras, HER-2/neu and DF3/MUC-1, coupled with evidence that humoral and cytotoxic T-cell responses against these antigens exist, the central dilemma facing tumor immunologists is why the host immune response is so inefficient. One possibility is that tumor cells themselves are either inefficient or ineffective antigen-presenting cells (APCs). The failure of tumor cells to function as APCs may be due to their inability to process and present the antigen, the absence or insufficient numbers of adhesion and costimulatory molecules or, potentially, the secretion of inhibitory cytokines. Therefore, we sought to determine whether human breast cancer cell lines could function as APCs and, if not, to identify mechanism(s) responsible for this defect. Here, we show that human breast cancer cell lines fail to present alloantigen. This defect does not reside in their inherent capacity to present antigen but rather is due to apoptosis of activated T cells induced by exposure to the breast carcinoma-associated mucin antigen, DF3/MUC1. These results support the hypothesis that DF3/MUC1 may contribute to the paucity of clinically significant anticarcinoma-specific immune responses.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8946837     DOI: 10.1038/nm1296-1367

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  22 in total

Review 1.  Mucins and blastocyst attachment.

Authors:  Amantha Thathiah; Daniel D Carson
Journal:  Rev Endocr Metab Disord       Date:  2002-05       Impact factor: 6.514

2.  Colonic epithelial cell mediated suppression of CD4 T cell activation.

Authors:  S M Cruickshank; L D McVay; D C Baumgart; P J Felsburg; S R Carding
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 3.  The acceptor specificity of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases.

Authors:  A P Elhammer; F J Kézdy; A Kurosaka
Journal:  Glycoconj J       Date:  1999-02       Impact factor: 2.916

4.  Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege.

Authors:  J O'Connell; M W Bennett; G C O'Sullivan; J O'Callaghan; J K Collins; F Shanahan
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

5.  Personalized characterization of diseases using sample-specific networks.

Authors:  Xiaoping Liu; Yuetong Wang; Hongbin Ji; Kazuyuki Aihara; Luonan Chen
Journal:  Nucleic Acids Res       Date:  2016-09-04       Impact factor: 16.971

6.  Tumor cells express FcgammaRI which contributes to tumor cell growth and a metastatic phenotype.

Authors:  M B Nelson; J K Nyhus; K I Oravecz-Wilson; E Barbera-Guillem
Journal:  Neoplasia       Date:  2001 Mar-Apr       Impact factor: 5.715

7.  Androgen-dependent regulation of human MUC1 mucin expression.

Authors:  Stephen Mitchell; Paul Abel; Sanjeev Madaan; James Jeffs; Khurram Chaudhary; Gordon Stamp; El-Nasir Lalani
Journal:  Neoplasia       Date:  2002 Jan-Feb       Impact factor: 5.715

8.  MUC1 induced by Epstein-Barr virus latent membrane protein 1 causes dissociation of the cell-matrix interaction and cellular invasiveness via STAT signaling.

Authors:  Satoru Kondo; Tomokazu Yoshizaki; Naohiro Wakisaka; Toshiyuki Horikawa; Shigeyuki Murono; Kyung Lib Jang; Irene Joab; Mitsuru Furukawa; Joseph S Pagano
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

9.  Increased lysis of stem cells but not their differentiated cells by natural killer cells; de-differentiation or reprogramming activates NK cells.

Authors:  Han-Ching Tseng; Aida Arasteh; Avina Paranjpe; Antonia Teruel; Wendy Yang; Armin Behel; Jackelyn A Alva; Gina Walter; Christian Head; Tomo-o Ishikawa; Harvey R Herschman; Nicholas Cacalano; April D Pyle; No-Hee Park; Anahid Jewett
Journal:  PLoS One       Date:  2010-07-16       Impact factor: 3.240

10.  Can immunotherapy by gene transfer tip the balance against colorectal cancer?

Authors:  S M Todryk; H Chong; R G Vile; H Pandha; N R Lemoine
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.